Wall Street brokerages expect Dare Bioscience Inc (NASDAQ:DARE) to post earnings of ($0.31) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Dare Bioscience’s earnings. Dare Bioscience posted earnings per share of ($0.28) in the same quarter last year, which would suggest a negative year-over-year growth rate of 10.7%. The company is expected to report its next earnings results on Monday, May 13th.

On average, analysts expect that Dare Bioscience will report full-year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.47) to ($1.10). For the next year, analysts forecast that the business will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.80) to ($0.86). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Dare Bioscience.

A number of analysts recently weighed in on DARE shares. Maxim Group restated a “buy” rating and set a $3.00 target price on shares of Dare Bioscience in a research note on Thursday, April 4th. ValuEngine upgraded shares of Dare Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.

Shares of DARE stock traded down $0.01 during trading hours on Wednesday, reaching $1.05. 387,900 shares of the stock were exchanged, compared to its average volume of 971,558. Dare Bioscience has a 12-month low of $0.60 and a 12-month high of $3.25. The firm has a market capitalization of $11.99 million, a price-to-earnings ratio of -0.85 and a beta of 2.35.

In other news, Director Roger Hawley bought 454,545 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The shares were purchased at an average cost of $1.10 per share, for a total transaction of $499,999.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 19.00% of the stock is currently owned by corporate insiders.

An institutional investor recently raised its position in Dare Bioscience stock. Geode Capital Management LLC raised its stake in Dare Bioscience Inc (NASDAQ:DARE) by 80.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,470 shares of the biotechnology company’s stock after purchasing an additional 47,170 shares during the period. Geode Capital Management LLC owned 0.92% of Dare Bioscience worth $73,000 as of its most recent SEC filing. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

See Also: What is the NASDAQ Stock Market?

Get a free copy of the Zacks research report on Dare Bioscience (DARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.